Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2017

View Archived Issues

OBI Pharma acquires TH-3424 from Threshold Pharmaceuticals

Universita degli Studi di Sassari patents amniotic cells with phagocytic activity

Etelcalcetide receives U.S. orphan designation for pediatric hyperparathyroidism

Baltaleucel-T cell therapy given FDA orphan status for post-transplant lymphoproliferative disorder

ReNeuron reports FDA feedback for CTX stroke disability program

U.S. orphan designation given to recombinant fibroblast growth factor receptor 3 for achondroplasia

PeptiDream, Shionogi and Sekisui Chemical form new company

UMB grants rights to vaccine technology to Serenta Biotechnology

Crestone presents promising phase I data for CRS-3123

Adocia begins two studies of BioChaperone products for diabetes

Sevion Therapeutics to acquire Eloxx Pharmaceuticals

First patient enrolled in DELIVERS trial of Castle Creek Pharmaceuticals' CCP-020

Merck KGaA collaborates with F-star on bispecific immuno-oncology antibodies

Pain Therapeutics awarded NIH grant to advance Alzheimer's disease drug candidate

Researchers develop a novel assay to quantify inducible, replication competent latent HIV-1

First-in-human results reported for novel antifungal VL-2397

KGF does not improve clinical outcome in patients with acute respiratory distress syndrome

Debiopharm reports first-in-human data for FGFR inhibitor Debio-347

Novo Nordisk grants exclusive rights to IPH-5401 to Innate Pharma

MaxCyte enters CRADA with NIAID on X-linked chronic granulomatous disease

Amgen submits applications in E.U. and U.S. for CV outcomes data for Repatha

ACEA and Memorial Sloan Kettering collaborate on personalized CAR T-cell therapy

Cel-Sci responds to FDA regarding clinical hold on phase III study of Multikine

Novartis and Bristol-Myers Squibb collaborate to evaluate Mekinist with Opdivo in colorectal cancer

AntriaBio submits IND application for AB-101

Velo Bio enrolls first patient in phase IIb/IIIa study of digoxin immune Fab

First clinical data presented for the anti-TNFRSF18 agonist BMS-986156 in solid tumors

Cornerstone Pharmaceuticals announces name change

Survival data reported for CMB-305 in NY-ESO-1+ recurrent soft tissue sarcomas

BMS and Seattle Genetics to test nivolumab/brentuximab vedotin combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...